Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy
Background: Although biologics introduced a new era in psoriasis care when available a decade ago, it is unclear to what extent the available systemic treatments treat patients adequately. Objective: To analyse the clinical severity and quality of life of the psoriasis population in Sweden treated w...
Main Authors: | J. M. Norlin, P. S. Calara, U. Persson, M. Schmitt-Egenolf |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-08-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09546634.2017.1289147 |
Similar Items
-
The Influence of Socioeconomic Factors on Access to Biologics in Psoriasis
by: Jenny M. Norlin, et al.
Published: (2023-11-01) -
Psoriasis: Correlation between severity index (PASI) and quality of life index (DLQI) based on the type of treatment
by: Ali Al Raddadi, et al.
Published: (2016-01-01) -
Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life
by: Sascha Gerdes, et al.
Published: (2020-07-01) -
Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab
by: Boni E. Elewski, et al.
Published: (2017-08-01) -
Assessing the Impact of Improvements in PASI and Itch Scores on Patients’ Quality of Life in the Treatment of Psoriasis
by: Gil Yosipovitch, et al.
Published: (2019-07-01)